BASF is pressing ahead on two distinct fronts: the planned sale of its coatings arm to private equity firm Carlyle is expected to close in the second quarter of 2026, while a newly commissioned fermentation plant in Ludwigshafen marks the company’s deeper push into biological crop protection. The moves come as the stock, up nearly 18% year-to-date, shows signs of short-term overextension.
The coatings transaction, disclosed during a BMO Farm to Market conference in New York, is subject to regulatory clearance. Divesting the business is part of a broader portfolio clean-out that also includes the monetisation of oil and gas assets. Management’s goal is to sharpen BASF’s focus on core chemical production and emerging projects such as the BioHub fermentation site.
That BioHub — a high-double-digit-million-euro investment — has already begun commercial production of key active ingredients. Microorganisms transform renewable feedstocks like glucose into biological fungicides and seed treatment products. Among the first outputs are Bacillus amyloliquefaciens, the basis of the Serifel fungicide, and the active ingredient core of Inscalis, an insecticide derived from Penicillium coprobium. By scaling fermentation in-house, BASF reduces reliance on external partners and gains supply chain resilience.
The agricultural solutions unit was elevated to a standalone segment in May 2026, gaining greater entrepreneurial autonomy. Research and development spending in the division reached €990 million last year. The segment’s first-quarter performance was solid, with volume growth driven largely by China, though the Middle East conflict has weighed on logistics since March.
Should investors sell immediately? Or is it worth buying BASF?
On the chemicals side, BASF has raised prices for additives used in plastic applications, citing supply-chain disruptions and rising raw material costs linked to the geopolitical tension. The adjustment is designed to protect margins in the performance chemicals unit. Management held its full-year outlook steady after posting first-quarter EBITDA before special items of €2.4 billion.
Despite the operational momentum, the stock’s recent rally has cooled. Shares closed Friday at €52.63, down 1.31%, and sit about 4% below the 52-week high of €54.70 reached in April. The relative strength index stands at 70.5, a level that typically signals a near-term overbought condition. Goldman Sachs has lifted its price target to €65, but the resistance band between €55 and €55.50 has yet to be breached decisively.
A signal from inside the boardroom may offer some reassurance. Chief Financial Officer Dirk Elvermann purchased BASF shares on 8 May at €50.91, for a total outlay of €45,819. Such insider buying does not replace earnings reports, but it indicates management conviction at current levels.
Looking ahead, the company has scheduled a virtual deep dive into its Zhanjiang Verbund site in China for 8 June, an event that should shed light on how concrete its Asian growth strategy has become. For now, the twin tracks of portfolio simplification and biological agriculture investment are both on schedule — even if the stock is taking a breather after a powerful run.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from May 16 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 16.
BASF: Buy or sell? Read more here...
